Sugi Predict

Sugi Predict / Compounds / SCHEMBL29377468

SCHEMBL29377468

SCHEMBL29377468

CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)Cc1ccccc1)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O

nearest known ligand 0.73

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CALCR P30988 4/20 0.73
▸ TFPI P10646 4/20 0.71
▸ NPY2R P49146 6/20 0.67
▸ NPY4R P50391 6/20 0.67
▸ NPY5R Q15761 6/20 0.67
▸ NPY1R P25929 4/20 0.67
▸ CRHR1 P34998 1/20 0.66
▸ CRHR2 Q13324 1/20 0.66
▸ GLP1R P43220 3/20 0.66
▸ GCGR P47871 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30495699 0.97 CALCR (0.73) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL29522561 0.94 CALCR (0.69) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL30001037 0.93 CALCR (0.78) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL30001479 0.93 CALCR (0.80) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL31182518 0.93 CALCR (0.69) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL29939723 0.92 CALCR (0.79) CALCRNPY2RNPY4RNPY5RNPY1R
SCHEMBL30686824 0.92 CALCR (0.75) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL30686828 0.92 CALCR (0.75) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL30686821 0.92 CALCR (0.75) CALCRTFPINPY2RNPY4RNPY5R
SCHEMBL30686816 0.92 CALCR (0.75) CALCRTFPINPY2RNPY4RNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683714-A1 OBESTATIN FOR USE AS ANTINEOPLASTIC AGENT IN THE TREATMENT OF PANCREATIC CANCER Servizo Galego de Saude (ES) 2026-01-28 — — EP claimed
US-20250327817-A1 DETECTION OF PREDICTORS OF PREECLAMPSIA UNIV IOWA RES FOUND (US) 2025-10-23 — — US claimed
US-20250154113-A1 Microcrystalline Diketopiperazine Compositions and Methods WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2025-05-15 — — US claimed
US-12297227-B2 Method for extracting target protein from biological sample and method for analyzing target protein MEDIFORD CORPORATION (JP) 2025-05-13 — — US claimed
CN-119584992-A Antibody-drug conjugates comprising antibodies against human TROP2 and uses thereof 瑞嘉化学生物科学股份有限公司 2025-03-07 — — CN claimed
EP-4454709-A2 FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS FibroBiologics, Inc. (US) 2024-10-30 — — EP claimed
EP-3810159-B1 FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS FIBROBIOLOGICS INC (US) 2024-10-16 — — EP claimed
WO-2024194459-A1 OBESTATIN FOR USE AS ANTINEOPLASTIC AGENT IN THE TREATMENT OF PANCREATIC CANCER SERVIZO GALEGO DE SAÚDE (ES) 2024-09-26 — — WO claimed
EP-4434579-A1 OBESTATIN FOR USE AS ANTINEOPLASTIC AGENT IN THE TREATMENT OF PANCREATIC CANCER Servizo Galego de Saude (ES) 2024-09-25 — — EP claimed
US-20240293469-A1 FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS FIGENE, LLC (US) 2024-09-05 — — US claimed
US-20230263800-A1 COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION FRED HUTCHINSON CANCER CENTER (US) 2023-08-24 — — US claimed
US-11667688-B2 Glucagon derivative and a composition comprising a long acting conjugate of the same HANMI PHARM. CO., LTD. (KR) 2023-06-06 — — US claimed
EP-2440184-B1 DIKETOPIPERAZINE MICROPARTICLES WITH DEFINED SPECIFIC SURFACE AREAS MANNKIND CORP (US) 2023-04-05 — — EP claimed
WO-2022262837-A1 GLUCAGON ANALOG AND MEDICAL USE THEREOF 北京拓界生物医药科技有限公司 2022-12-22 — — WO claimed
US-20220237496-A1 QUANTUM MEMORY AND ASSOCIATED APPLICATIONS CADET, Xavier (FR) 2022-07-28 — — US claimed
EP-3587404-B1 MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF MANNKIND CORP (US) 2022-07-13 — — EP claimed
WO-2022098776-A1 COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2022-05-12 — — WO claimed
US-20220127325-A1 GLUCAGON DERIVATIVE AND A COMPOSITION COMPRISING A LONG ACTING CONJUGATE OF THE SAME HANMI PHARM. CO., LTD. (KR) 2022-04-28 — — US claimed
US-11261227-B2 Glucagon derivative and a composition comprising a long acting conjugate of the same HANMI PHARM. CO., LTD. (KR) 2022-03-01 — — US claimed
US-20220048868-A1 Microcrystalline Diketopiperazine Compositions and Methods WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2022-02-17 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263800-A1 COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION BMP4, P2RY2, GPR39 CALCR 28/4885TFPI 2848/4885NPY2R 452/4885
US-20220048868-A1 Microcrystalline Diketopiperazine Compositions and Methods RRP15, DKK1, SPOP CALCR 3909/4885TFPI 2158/4885NPY2R 180/4885
US-20250154113-A1 Microcrystalline Diketopiperazine Compositions and Methods RRP15, DKK1, SPOP CALCR 3909/4885TFPI 2158/4885NPY2R 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback